Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Cross-over, Placebo-controlled, Multi-center, Phase 2a Study to Assess the Safety and Signal in Efficacy of BAY 2395840 in Patients With Diabetic Neuropathic Pain

NCT05219812 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT05219812
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05219812 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Cross-over, Placebo-controlled, Multi-center, Phase 2a Study to Assess the Safety and Signal in Efficacy of BAY 2395840 in Patients With Diabetic Neuropathic Pain
Lead sponsor
Bayer
Phase
Phase 2
Overall status
Completed
Start date
February 16, 2022
Completion date
November 21, 2022
Enrollment
80 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes mellitus, neuropathic pain associated with diabetic peripheral neuropathy, peripheral neuropathic pain